Wells Fargo
AVBP icon

Wells Fargo’s ArriVent BioPharma AVBP Stock Holding History

Wells Fargo’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
36,670
+24,546
+202% +$724K ﹤0.01% 3946
2026
Q1 		$280K Sell
12,124
-20,156
-62% -$455K ﹤0.01% 4490
2025
Q4 		$649K Buy
32,280
+17,101
+113% +$356K ﹤0.01% 4293
2025
Q3 		$280K Buy
15,179
+3,276
+28% +$64.4K ﹤0.01% 4724
2025
Q2 		$259K Sell
11,903
-2,916
-20% -$60.5K ﹤0.01% 4616
2025
Q1 		$274K Buy
14,819
+326
+2% +$7.98K ﹤0.01% 4483
2024
Q4 		$386K Buy
14,493
+4,139
+40% +$119K ﹤0.01% 4355
2024
Q3 		$243K Buy
10,354
+6,751
+187% +$153K ﹤0.01% 4449
2024
Q2 		$66.8K Buy
3,603
+372
+12% +$6.63K ﹤0.01% 5166
2024
Q1 		$57.7K Buy
+3,231
New +$65.2K ﹤0.01% 5197

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's AVBP Position: Q2 2026 in Review

Wells Fargo increased its ArriVent BioPharma (AVBP) stake by 202% in Q2 2026, buying an estimated $724K and bringing the position to 36,670 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3946.

Wells Fargo first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Wells Fargo held 36,670 shares of ArriVent BioPharma worth $1.27M as of Q2 2026.
  • Wells Fargo bought 24,546 ArriVent BioPharma shares in Q2 2026, an estimated $724K.
  • ArriVent BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3946 holding.
  • Wells Fargo first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.